nach oben

Drugs

Erschienen in:

01.03.2013 | Leading Article

Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research

verfasst von: Cristan Farmer, Audrey Thurm, Paul Grant

Erschienen in: Drugs | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The current review covers extant literature on pharmacotherapy for core symptoms of autism. The core symptoms of autism include impairments in social interaction and communication, as well as the presence of restricted and repetitive behaviors. There are no known efficacious treatments for the core social symptoms, although effects on repetitive behaviors are indicated with some data. While studies of fenfluramine, secretin, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics. Newer lines of research, including cholinergic and glutamatergic agents and oxytocin, will be of considerable interest in the future. However, research on the treatment of core symptoms is plagued by limitations in study design, statistical power, and other issues inherent to the study of treatments for autism (e.g., heterogeneity of the disorder) that continue to prevent the elucidation of efficacious treatments.

American Psychological Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington: American Psychiatric Association; 2000.

Lord C, Jones RM. Annual research review: re-thinking the classification of autism spectrum disorders. J Child Psychol Psychiatry. 2012;53(5):490–509.PubMedCrossRef

Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33(5):527–34.PubMedCrossRef

Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121(3):e441–8.PubMedCrossRef

Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. J Autism Dev Disord. 2012;42(8):1592–605.PubMedCrossRef

Lecavalier L, Aman MG, Hammer D, Stoica W, Mathews GL. Factor analysis of the Nisonger child behavior rating form in children with autism spectrum disorders. J Autism Dev Disord. 2004;34(6):709–21.PubMedCrossRef

Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord. 2006;36(7):849–61.PubMedCrossRef

Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–9.PubMedCrossRef

Farmer CA, Aman MG. Aripiprazole for the treatment of irritability associated with autism. Expert Opin Pharmacother. 2011;12(4):635–40.PubMedCrossRef

10.

Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9(5):343–54.PubMedCrossRef

11.

Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother. 2012;13(11):1615–29.PubMedCrossRef

12.

Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr. 1996;8(4):348–54.PubMedCrossRef

13.

Geller E, Ritvo ER, Freeman BJ, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med. 1982;307(3):165–9.PubMedCrossRef

14.

Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, et al. Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull. 1986;22(1):133–40.PubMed

15.

Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, et al. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27(4):434–9.PubMedCrossRef

16.

Stern LM, Walker MK, Sawyer MG, Oades RD, Badcock NR, Spence JG. A controlled crossover trial of fenfluramine in autism. J Child Psychol Psychiatry. 1990;31(4):569–85.PubMedCrossRef

17.

Leventhal BL, Cook EH, Morford M, Ravitz AJ, Heller W, Freedman DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatr Clin Neurosci. 1993;5(3):307–15.

18.

Sherman J, Factor DC, Swinson R, Darjes RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989;19(4):533–43.PubMedCrossRef

19.

Panksepp J, Najam N, Soares F. Morphine reduces social cohesion in rats. Pharmacol Biochem Behav. 1979;11(2):131–4.PubMedCrossRef

20.

Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006;40(6):1086–95.PubMedCrossRef

21.

Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32(6):1283–91.PubMedCrossRef

22.

Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58(3):203–15.PubMedCrossRef

23.

Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995;58(3):191–201.PubMedCrossRef

24.

Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9–15.PubMed

25.

Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003495.

26.

Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62(7):530–4.PubMedCrossRef

27.

Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9(2):209–13.PubMedCrossRef

28.

Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, et al. Children’s Yale-Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):844–52.PubMedCrossRef

29.

Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990–8.PubMedCrossRef

30.

Yasuhara A. Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). Brain Dev. 2010;32(10):791–8.PubMedCrossRef

31.

Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31(2):175–81.PubMedCrossRef

32.

Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006;21(6):363–7.PubMedCrossRef

33.

Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–21.CrossRef

34.

Aman M, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485–91.PubMed

35.

McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142–8.PubMedCrossRef

36.

Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):E634–41.PubMedCrossRef

37.

Aman MG, Tasse MJ, Rojahn J, Hammer D. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17(1):41–57.PubMedCrossRef

38.

Scahill L, Hallet T, Aman M, Arnold LE, McDougle C, McCracken J, et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord. 2013;24(3):739–46.

39.

Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1143–54.PubMedCrossRef

40.

Sparrow S, Balla D, Cicchetti D. Vineland adaptive behavior scales: survey form manual. Circle Pines: American Guidance Service; 1984.

41.

Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 2012;223(2):237–45.CrossRef

42.

Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9.PubMedCrossRef

43.

Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–40.PubMedCrossRef

44.

Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72(9):1270–6.PubMedCrossRef

45.

Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50(6):441–7.PubMedCrossRef

46.

Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl. 1978;271:5–27.PubMedCrossRef

47.

Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440–4.PubMedCrossRef

48.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583–90.PubMedCrossRef

49.

Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582–9.PubMedCrossRef

50.

Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012;169(3):292–9.PubMedCrossRef

51.

McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001–8.PubMedCrossRef

52.

Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol. 2006;16(1–2):181–6.PubMedCrossRef

53.

Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;17(4):787–801.PubMedCrossRef

54.

Deutsch SI, Urbano MR, Neumann SA, Burket JA, Katz E. Cholinergic abnormalities in autism: is there a rationale for selective nicotinic agonist interventions? Clin Neuropharmacol. 2010;33(3):114–20.PubMedCrossRef

55.

Chez M, Buchanan T, Becker M, Kessler J, Aimonovitch M, Mrazek S. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1(2):83–8.

56.

Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: childhood Autism rating scale (CARS). J Autism Dev Disord. 1980;10(1):91–103.PubMedCrossRef

57.

Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12(3):237–41.PubMedCrossRef

58.

Doyle RL, Frazier J, Spencer TJ, Geller D, Biederman J, Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006;9(3):543–9.PubMedCrossRef

59.

Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, et al. An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21(4):353–7.PubMedCrossRef

60.

Niederhofer H. Treating autism pharmacologically: also tacrine might improve symptomatology in some cases. J Child Neurol. 2007;22(8):1054. (author reply 1054–5).PubMedCrossRef

61.

Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19(3):165–9.PubMed

62.

Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):621–9.PubMedCrossRef

63.

Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ. 2002;325(7377):1422.PubMedCrossRef

64.

Arnold LE, Aman MG, Hollway J, Hurt E, Bates B, Li X, et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. J Child Adolesc Psychopharmacol. 2012;22(3):198–205.PubMedCrossRef

65.

McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry. 2005;66(Suppl 10):9–18.PubMed

66.

Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21–7.PubMedCrossRef

67.

Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of d-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115–7.PubMedCrossRef

68.

King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658–65.PubMedCrossRef

69.

Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191(1):141–7.PubMedCrossRef

70.

Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574–9.PubMedCrossRef

71.

Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):517–24.PubMedCrossRef

72.

Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clini Psychopharmacol. 2007;27(3):317–8.CrossRef

73.

Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(6):565–9.PubMedCrossRef

74.

Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with Autism. Biol Psychiatry. 2012;71(11):956–61.PubMedCrossRef

75.

Chadman KK, Guariglia SR, Yoo JH. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin Drug Discov. 2012;7(5):407–16.PubMedCrossRef

76.

Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010;65(6):768–79.PubMedCrossRef

77.

Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692–4.PubMedCrossRef

78.

Ellenbogen MA, Linnen AM, Grumet R, Cardoso C, Joober R. The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces. Psychophysiology. 2012;49(1):128–37.PubMedCrossRef

79.

Rimmele U, Hediger K, Heinrichs M, Klaver P. Oxytocin makes a face in memory familiar. J Neurosci. 2009;29(1):38–42.PubMedCrossRef

80.

Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology. 2003;28(1):193–8.PubMedCrossRef

81.

Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61(4):498–503.PubMedCrossRef

82.

Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000;21(5):347–50.PubMedCrossRef

83.

Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008;69(10):1513–28.PubMedCrossRef

84.

Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 gene in Fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra1.PubMedCrossRef

85.

Aman MG, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow KD, et al. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004;9(1):36–47.PubMed

86.

Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659–85.PubMedCrossRef

87.

Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3):205–23.PubMedCrossRef

88.

Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, et al. Children’s Yale-Brown obsessive compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1114–23.PubMedCrossRef

89.

Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with Fragile X syndrome: a retrospective chart review. Autism Res Treat. 2012;2012:104317.PubMed

90.

Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1):1–5.PubMedCrossRef

91.

Krueger DD, Bear MF. Toward fulfilling the promise of molecular medicine in Fragile X syndrome. Annu Rev Med. 2011;62:411–29.PubMedCrossRef

92.

Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. J Autism Dev Disord. 2012;42(3):432–40.PubMedCrossRef

Titel: Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research
verfasst von: Cristan Farmer
Audrey Thurm
Paul Grant
Publikationsdatum: 01.03.2013
Verlag: Springer International Publishing AG
Erschienen in: Drugs / Ausgabe 4/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0021-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments

Promising New Molecular Targeted Therapies in Head and Neck Cancer

Targeting Interleukin-6 in Rheumatoid Arthritis

Lixisenatide: First Global Approval

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?

Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure